ClinicalTrials.gg
RecruitingNCT04558723CMR-ICDUpdated May 13, 2024

Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy

An interventional study of ICD/CRT-D implantation in Non-ischemic Dilated Cardiomyopathy, sponsored by Prof. Dr. med. Ingo Eitel. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Prof. Dr. med. Ingo Eitel · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cardiomyopathy, Dilated with a site in Germany — 4 open to participants now, 5 under way, none of them phase 3. Cardiomyopathy, Dilated · Germany.

Planned enrollment
Largest of 12
760 · median 72
Started
2021
with 1 other
No phase
6 of 23
1 open now
Registered
20th of 23
by date

Among the 23 studies in Cardiomyopathy, Dilated with a site in Germany, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 with no phase, and was the 20th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

4 of the 23 studies in Cardiomyopathy, Dilated with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cardiomyopathy, Dilated with a site in Germany, or all of them as a file.
02

Study summary

Patients with diagnostic CMR images for assessment of LGE/fibrosis and evidence/presence of non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups in a 1:1 ratio: ICD group or Optimal HF care group.

Read the detailed description

The primary objective of this study is to evaluate the hypothesis that implantable cardioverter defibrillator (ICD) therapy would decrease the risk of death from any cause in comparison to optimal heart failure (HF) care without ICD insertion in patients with NIDCM, left ventricular ejection fraction (LVEF) ≤35% and presence of myocardial fibrosis on cardiac magnetic resonance (CMR) imaging.

03

Conditions studied

  • Non-ischemic Dilated Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NIDCM (idiopathic or familial)*
  • ≤35% and presence of fibrosis on CMR
  • Diagnostic CMR scan
  • Age ≥18 years
  • Written
  • Ability to give informed consent

Exclusion criteria

Exclusion Criteria:

  • ICM [previous myocardial infarction, previous percutaneous coronary intervention]
  • Other cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathies [e.g. cardiac amyloidosis, cardiac sarcoidosis, hemochromatosis and iron overload cardiomyopathy], left ventricular non-compaction cardiomyopathy, reversible cardiomyopathies [Takotsubo syndrrome, peripartum cardiomyopathy, chemotherapy induced cardiomyopathy].
  • Myocarditis
  • for CMR at study entry (including severe claustrophobia, pacemaker or ICD, metallic cerebral or intracranial implants, known allergy to gadolinium)
  • Severe renal insufficiency ( \<30 mL/min)
  • Current pacemaker or defibrillator in situ
  • Current indication for device therapy (e.g. secondary prophylaxis after aborted SCD)
  • Renal impairment defined as an \<30 milliliters
  • Age \<18 years
  • Patients presenting with pregnancy
  • Patients without
  • Participation in another randomized trial
  • \<2 years
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
760 participants (estimated)

Study arms

  • Experimental
    ICD group

    Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.

    Other: ICD/CRT-D implantation

  • No intervention
    Optimal HF care group

    Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.

Interventions

  • OtherICD/CRT-D implantation

    ICD/CRT-D implantation (if indicated)

06

What researchers measure

Primary outcomes

  1. Death from any cause

    Death from any causes during follow-up - after discharge.

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
  • Universität zu Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
    • Ingo Eitel, Prof. Dr. med. · Contact
    • Thomas Stiermaier, Dr.med · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Nov 2027, 82 months after the start.

Of 28 interventional studies with no phase under Cardiomyopathy, Dilated, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 73. This study's planned 82 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 22, 2020
StartActual
Jan 14, 2021
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04558723
Lead sponsor
Prof. Dr. med. Ingo Eitel
Collaborators
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Responsible party
Prof. Dr. med. Ingo Eitel (Director, University of Luebeck) — Sponsor-investigator
First posted
Sep 22, 2020
Start date
Jan 14, 2021
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
May 13, 2024

Study contacts

Ingo Eitel, Prof. Dr.
Contact
ingo.eitel@uksh.de
+49 451 500 44501
Thomas Stiermaier, Dr.
Contact
thomas.stiermaier@uksh.de
+49 451 500 44501
Ingo Eitel, Prof. Dr.
principal investigator · Medical Clinic II - University Heart Center Lübeck

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion